Aignostics is an AI startup that turns complex multimodal pathology data into transformative insights. In a recent development, the company has raised $34 million in Series B funding. With this, the total funding secured by the company to date accounts for $55 million.
The oversubscribed round was led by ATHOS, with investments from Mayo Clinic and growth financing from HTGF, which recently invested in ABH Optics and autarkize, alongside support from existing investors Wellington Partners, Boehringer Ingelheim Venture Fund, CARMA Fund, and VC Fonds Technologie managed by IBB Ventures.
Fund utilisation
The new funding will strengthen Aignostics’ offerings for target ID, translational research, and companion diagnostics (CDx), and support several strategic initiatives, including the launch of scaled “plug-and-play” products for a range of indications and tasks, including tumor microenvironment and biomarker profiling. It will also focus on continued expansion into the US with additional headcount and support for US partners, and collaborative development of foundation models and biopharma product offerings with Mayo Clinic.
AI for precision medicine
As precision medicine becomes more nuanced and complex, biopharmaceutical companies are increasingly turning to AI to enhance the utility, performance, and scalability of computational pathology analyses for drug development and diagnostics. In parallel, machine learning technologies are rapidly evolving, producing AI models with record accuracy and robustness, opening new avenues for biopharmaceutical research and diagnostics.
Founded in 2018 as a spin-off of Charité Berlin and the Berlin Institute of Health by Viktor Matyas, Frederick Klauschen, Klaus-Robert Müller, and Maximilian Alber, Aignostics uses a variety of clinical data, technology, and scientific methods to develop products and services for precision medicine.
“2024 has been a pivotal year for us that has included a major strategic collaboration with Bayer and the launch of our first foundation model, RudolfV,” said Viktor Matyas, CEO and Co-Founder of Aignostics. “With RudolfV, we’ve gained the ability to quickly develop cost-efficient algorithms that generalise to the real world. Now with this new round of funding, we’re turning our most popular algorithms into products that will help usher in an era of truly generalisable AI for computational pathology.”
“We know that digital pathology, paired with the vast capabilities of AI, has immense potential to impact diagnosis and treatment for patients. Mayo Clinic is actively charting the new frontier of predictive and personalised care,” shared Jim Rogers, CEO of Mayo Clinic Digital Pathology.
“At its core, Aignostics is a world-class machine learning company,” said Julian Zachmann from ATHOS. “The field is advancing so quickly that, in order to succeed, AI companies need to avoid flashy distractions, stay laser focused on the highest-quality science, and relentlessly innovate. Aignostics is doing just that and bringing a level of transparency and rigor to its biopharmaceutical clients that we think is truly unique.”
The post Aignostics raises $34M to transform precision medicine with AI appeared first on Tech Funding News.